The five-year relative survival rate for metastatic breast cancer is about 32.6%, based on data from the National Cancer Institute’s SEER program covering 2015 to 2021. That means roughly one in three women diagnosed with distant-stage breast cancer are alive five years later. While this number is significantly lower than earlier-stage disease, it has improved steadily over the past two decades, and individual outcomes vary widely depending on the cancer’s biology, where it has spread, and how it responds to treatment.
What the Overall Numbers Show
Metastatic breast cancer, also called stage IV, means the cancer has spread beyond the breast and nearby lymph nodes to distant organs such as the bones, lungs, liver, or brain. About 6% of all breast cancer cases are diagnosed at this stage. The 32.6% five-year survival rate is a population average, which means it reflects outcomes across all ages, subtypes, and treatment histories. It does not predict what will happen to any one person.
Median survival, the point at which half of patients are still alive, has also been climbing. A study tracking patients at a routine oncology practice found that median overall survival rose from about 32 months for those diagnosed between 1995 and 2000 to roughly 48 months for those diagnosed between 2018 and 2022. That’s a gain of more than a year and a half in median survival over two decades, driven largely by newer targeted therapies.
Approximately 13% of women with stage IV breast cancer survive 10 years or longer. Younger women have a slight edge here: the 10-year breast cancer-specific survival rate is about 15.7% for women diagnosed at age 40 or younger, compared to 11.7% for women between 51 and 70.
How Cancer Subtype Affects Survival
Breast cancer is not one disease. Pathologists classify tumors by whether they carry hormone receptors (HR) and a protein called HER2, and these subtypes respond differently to treatment. Overall five-year relative survival rates across all stages illustrate the gap:
- HR-positive/HER2-negative: 95.6% across all stages. This is the most common subtype and typically the slowest growing. It responds to hormone-blocking therapies, and when it does spread, it often moves to bone first, which generally carries a better prognosis than spread to organs like the brain or liver.
- HR-positive/HER2-positive: 91.8% across all stages. These cancers benefit from both hormone therapy and HER2-targeted drugs.
- HR-negative/HER2-positive: 86.5% across all stages. Newer antibody-drug conjugates have made a notable difference here. One such therapy showed a median overall survival benefit of 12.7 months compared to standard treatment in patients with HER2-positive metastatic disease.
- Triple-negative (HR-negative/HER2-negative): 78.4% across all stages. This subtype is the most aggressive, with fewer targeted treatment options, though immunotherapy has begun to improve outcomes for some patients.
These figures include all stages combined, so they don’t isolate metastatic disease alone. But the pattern holds: hormone receptor-positive cancers generally carry better survival even after spreading, while triple-negative disease remains the hardest to treat once metastatic.
Where the Cancer Spreads Matters
Not all metastatic breast cancer behaves the same way, and one of the biggest factors is which organs are involved. Bone-only metastasis tends to have the most favorable outlook among metastatic sites, with a five-year overall survival rate of about 22.8%. That number drops when cancer also involves the liver, lungs, or brain.
Brain metastasis carries the worst prognosis. When cancer has spread to the brain alongside bone, survival outcomes decline significantly. The same is true for liver involvement. Having metastasis in multiple organs at once compounds the challenge, because it limits treatment options and suggests a more aggressive disease biology. Patients with a single site of spread, particularly bone, tend to live longer and respond better to systemic treatment.
Age and Survival
Younger patients with metastatic breast cancer generally live longer than older ones. A large population-based study found that the five-year overall survival rate was 42.1% for young patients, 34.8% for middle-aged patients, 28.3% for older patients, and 11.8% for the oldest group. Part of this gap reflects biology: younger patients may have more resilient overall health and tolerate aggressive treatment better. But part of it is also about treatment patterns. Older patients are less likely to receive surgery, radiation, or chemotherapy, which contributes to the survival difference across every cancer subtype and metastatic site studied.
De Novo vs. Recurrent Metastatic Disease
There is an important distinction between people diagnosed with metastatic breast cancer from the start (called de novo) and those whose earlier-stage cancer returns as metastatic disease (recurrent). Somewhat counterintuitively, de novo metastatic patients tend to have better survival than those who relapse, particularly those who relapse quickly.
Patients who developed metastatic disease within 12 months of their original diagnosis had more than twice the risk of death compared to de novo patients. Even those who relapsed after five or more years showed worse long-term outcomes. A review of long-term survivorship found 10-year survival rates of about 12.5% for de novo patients, compared to just 1.7% for those who relapsed within two years. The likely explanation is that cancers which return despite prior treatment have already demonstrated resistance to therapy, making them harder to control the second time around.
Why Survival Rates Keep Improving
The steady climb in median survival from roughly 32 months in the late 1990s to nearly 48 months today reflects real therapeutic progress. For hormone receptor-positive disease, the addition of drugs that block cancer cell growth signals has extended the time before the disease worsens and improved overall survival. Patients diagnosed between 2015 and 2019 had a 22% lower risk of dying from any cause and a 27% lower risk of dying from breast cancer specifically, compared to those diagnosed in the early 1990s.
For HER2-positive disease, a newer generation of antibody-drug conjugates, which deliver chemotherapy directly to cancer cells, has produced striking results. One such treatment improved median survival by over a year compared to the physician’s choice of alternative therapy. These drugs have changed the trajectory for patients who previously had limited options after initial HER2-targeted treatment stopped working.
Triple-negative metastatic breast cancer has been slower to benefit from targeted advances, but the introduction of immunotherapy and newer drug combinations has begun to shift outcomes for patients whose tumors carry certain biological markers. This subtype still has the lowest survival rates, but the gap is narrowing.
Statistics capture a snapshot in time, reflecting patients diagnosed years ago who may not have had access to the treatments available today. For someone diagnosed now, the real-world outlook is likely somewhat better than what current five-year survival data suggest, because those numbers are still catching up to the latest therapies.